Clinical trials: Hematologic
Neoplasms, Febrile Neutropenia
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or linezolid as empiric therapy in febrile neutropenic…
- Trial name
- NCT02732327
- Testing
- CAZ-AVI, Vancomycin, Linezolid
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Forest Laboratories
Stroke, Acute
The Intravascular Cooling in the Treatment of Stroke 2/3 Trial
The purpose of this trial is to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.
- Trial name
- ICTuS2/3 (NCT01123161)
- Testing
- hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
- Where
- 31 sites in United States, Austria and 1 more
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Leukemia, Lymphoma
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00619645
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Severe Aplastic Anemia, Bone Marrow Failure Syndromes
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Our primary objective is to determine if it is feasible for SAA patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide with partially HLA-mismatched donors.
- Trial name
- NCT02224872
- Testing
- Bone marrow transplant, Thymoglobulin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00630994
- Testing
- Dacogen
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00567229
- Testing
- rituximab, lenalidomide, microarray analysis
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute
Randomized Double Cord Blood Transplant Study
The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin
- Trial name
- NCT00067002
- Testing
- Expanded allogeneic cord blood (CB), One Unmanipulated and One Expanded Cord Blood Unit, Rituxan
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia, Myelodysplastic Syndromes
A Study of ONO-7475 in Patients With Acute Leukemias
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability…
- Trial name
- NCT03176277
- Testing
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily
- Where
- 16 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Hemophilia
Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy
Trial to assess the bilateral deficit phenomenon during dynamic plantar flexion task in patients with haemophilic arthropathy Describe the differences in terms of the physical variables (muscular strength, range of motion and…
- Trial name
- PROPRIO-HE (NCT02165462)
- Testing
- Patients with haemophilia
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome
- Trial name
- NCT02065869
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part…
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- MT-3724NHL001 (NCT02361346)
- Testing
- MT-3724 Phase 1, MT-3724 Phase 2
- Where
- 41 sites in United States, Belarus and 8 more
- Volunteers
- 38 people
- Sponsor
- Molecular Templates, Inc.
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8))…
- Trial name
- guardian™1 (NCT00840086)
- Testing
- turoctocog alfa
- Where
- 63 sites in United States, Brazil and 16 more
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and…
- Conditions
- Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia
- Trial name
- NCT02709083
- Testing
- Dasatinib, Imatinib Mesylate, Nilotinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
The goals of this study are to learn about the effectiveness, the side-effects, if waiting to give the idarubicin and cytarabine may change the side effects or effectiveness, and to identify factors to predict for responses to…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT01607645
- Testing
- decitabine, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Juvenile Myelomonocytic Leukemia
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell…
- Trial name
- NCT00167219
- Testing
- Stem Cell Transplant, Preparative Regimen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Thrombocytopenia, Hematologic Diseases
Prospective Study of Patients With Thrombocytopenia Following HSCT
Isolated thrombocytopenia is a common and severe complication of HSCT, which often leads to an increased risk of life-threatening hemorrhage, frequent requirement of platelet transfusions and extended hospital stays, representing…
- Trial name
- NCT02487563
- Testing
- Decitabine, rhTPO, Conventional Treatment
- Where
- China
- Volunteers
- 97 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Sickle Cell Disease
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial
Many youth with chronic disease have difficulty taking medication every day and therefore do not receive full benefit from treatment.
- Trial name
- NCT03462511
- Testing
- HABIT Intervention, Standard of Care, Education materials
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Acute T-Cell Leukemia-Lymphoma
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
This study will examine the safety and effectiveness of Alemtuzumab (Campath-1H) for treating patients with adult T-cell leukemia/lymphoma (ATL).
- Trial name
- NCT00061048
- Testing
- Alemtuzumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Advanced Non-Hematologic Malignancies
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive…
- Trial name
- NCT00915278
- Testing
- PF-04605412
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.